风湿科医生与未使用过生物制剂的类风湿关节炎患者之间生物制剂起始对话的民族志观察研究
本研究采用民族志市场调研方法,对16名同意参与的风湿科医生与48名未使用过生物制剂的类风湿关节炎患者的就诊过程进行录像并由受过训练的民族志研究者访谈,分析生物制剂起始对话的内容、结构与时机。就诊平均约15分钟,其中生物制剂治疗讨论平均5.6分钟;48次就诊中45次提及皮下(SC)方案、35次提及静脉(IV)方案,77%(27/35)提及IV的就诊中医生未定义或描述IV给药,初始不熟悉IV的22例患者中19例就诊后仍不熟悉;所有16名风湿科医生均认为IV较SC不便,而46%(22/48)患者持此看法。
要点
- 48次就诊中45次提及皮下方案、35次提及静脉方案,讨论生物制剂平均5.6分钟。
- 77%(27/35)提及IV的就诊中医生未定义或描述IV给药,19/22例初始不熟悉IV者就诊后仍不熟悉。
- 16名医生均认为IV较SC不便,而46%(22/48)患者持此看法;部分患者表示困惑并希望有视觉辅助或要点总结。
核心结论
- 本研究揭示了改善生物制剂起始对话的重要教育机会,并显示患者与风湿科医生对IV治疗的认知存在差异。
研究设计与样本
- 民族志市场调研研究,对16名同意参与的风湿科医生与48名未使用过生物制剂的类风湿关节炎患者的就诊过程录像,并由受过训练的民族志研究者访谈。
- 分析生物制剂起始对话的内容、结构与时机。
主要发现
- 医生-患者就诊平均时长约15分钟,生物制剂治疗讨论平均5.6分钟。
- 48次就诊中,皮下(SC)与静脉(IV)治疗选项分别在45次和35次就诊中被提及。
- 所有患者对SC给药均有一定熟悉,但近半数患者(22/48)就诊前不熟悉IV治疗。
- 77%(27/35)提及IV治疗的就诊中,风湿科医生未对IV给药进行定义或描述;22例初始不熟悉IV的患者中19例就诊后仍不熟悉。
- 所有风湿科医生(16/16)认为IV治疗对患者不如SC治疗方便,而46%(22/48)患者持此看法。
关键数值与推荐
- 就诊平均时长约15分钟,生物制剂讨论平均5.6分钟。
- 48次就诊中SC被提及45次、IV被提及35次。
- 77%(27/35)提及IV的就诊中未定义或描述IV给药;19/22例初始不熟悉IV者就诊后仍不熟悉。
- 16/16名医生认为IV不如SC方便,46%(22/48)患者持此看法。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This ethnographic market research study investigated the biologic initiation conversation between rheumatologists and biologic-naive patients with rheumatoid arthritis to assess how therapy options, particularly mode of administration, were discussed. METHODS: Consenting rheumatologists (n = 16) and patients (n = 48) were videotaped during medical visits and interviewed by a trained ethnographer. The content, structure, and timing of conversations regarding biologic initiation were analyzed. RESULTS: The mean duration of physician-patient visits was approximately 15 minutes; biologic therapies were discussed for a mean of 5.6 minutes. Subcutaneous (SC) and intravenous (IV) therapy options were mentioned in 45 and 35 visits, respectively, out of a total of 48 visits. All patients had some familiarity with SC administration, but nearly half of patients (22 of 48) were unfamiliar with IV therapy going into the visit. IV administration was not defined or described by rheumatologists in 77% of visits (27 of 35) mentioning IV therapy. Thus, 19 of 22 patients who were initially unfamiliar with IV therapy remained unfamiliar after the visit. Disparities in physician-patient perceptions were revealed, as all rheumatologists (16 of 16) believed IV therapy would be less convenient than SC therapy for patients, while 46% of patients (22 of 48) felt this way. In post-visit interviews, some patients seemed confused and overwhelmed, particularly when presented with many treatment choices in a visit. Some patients stated they would benefit from visual aids or summary sheets of key points. CONCLUSION: This study revealed significant educational opportunities to improve the biologic initiation conversation and indicated a disparity between patients' and rheumatologists' perception of IV therapy.
引用
- Kottak N, Tesser J, Leibowitz E, et al. Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic-Naive Rheumatoid Arthritis Patients. Arthritis Care Res (Hoboken). 2018. PMID: 29381835. doi:10.1002/acr.23527
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。